TOP AGO TUMOR SECRETS

Hormonal therapy continues to be the cure of very first option for metastatic individuals with endocrine-responsive breast most cancers (LoE 1a A, AGO ++). The sequential use with the offered medicines depends on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is usually recommended